30 Aug Trial of CBD for children and teens with autism spectrum disorder
Clinicians at Seattle Children’s are trying to learn more about Autism Spectrum Disorder (ASD) and to examine the effects of an investigational medication, called GWP42003-P (a cannabidiol oral solution). We are conducting this study to look at whether or not this medicine helps communication, social skills, and patterns of behavior in children and adolescents with ASD. If your child is aged between 6 and 17 years, and has a diagnosis of ASD and episodes of irritability, please feel free to contact our study coordinator, Stacy Riffle, at 206-987-7502 or email SCACstudies@seattlechildrens.org to find out more.
Age 6-17 with a diagnosis of ASD and IQ of at least 70 (will confirm at screening)
Episodes of irritability or symptoms of ASD causing functional impairment or distress
Ability to swallow liquid medication.
Exclusions include current diagnoses of some mental disorders (for example schizophrenia), recent seizures, certain drugs (such as omeprazole), known or suspected history of alcohol or substance abuse, history of suicidal behavior.
Additional Study Details
Full Study Title
EXPLORATORY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF CANNABIDIOL ORAL SOLUTION (GWP42003P; CBD-OS) IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER
Gary Stobbe, MD
Karen Sporn, ARNP
Accepts Healthy Volunteers?
Seattle Children’s Hospital
4800 Sand Point Way NE
Seattle, Washington 98105
Seattle Children’s Autism Center
4909 25th Ave NE
Seattle Washington 98105